Nicotibine (Isoniazid)

Isoniazid is a pro‑drug that is activated by the bacterial enzyme KatG inside Mycobacterium tuberculosis. The activated compound blocks the synthesis of mycolic acids, essential lipids in the bacterial cell wall, leading to cell death and eradication of the infection.

The specific dose of Nicotibine is determined by the prescribing clinician based on the patient’s age, weight, disease severity, and treatment guidelines. Dosage regimens are individualized and should follow the prescriber’s instructions and local protocols.

Safety data for isoniazid in pregnancy are limited, and the drug is classified as having an unknown pregnancy category. It should be used only when the potential benefit outweighs any possible risk to the fetus. Breastfeeding mothers should consult their healthcare provider before use.

To order Nicotibine, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams across international markets, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Isoniazid is the cornerstone of first‑line antitubercular therapy, offering potent activity against replicating Mycobacterium tuberculosis. Compared with other classes such as fluoroquinolones or newer agents, isoniazid is generally less expensive and has a well‑established safety profile, but it carries a higher risk of hepatotoxicity and requires pyridoxine supplementation in some patients.

Store Nicotibine tablets at ambient temperature, below 25 °C, in the original container to protect them from moisture and direct sunlight. Keep the medication out of reach of children and avoid storing it in humid environments such as bathrooms.

Nicotibine is taken orally, usually once daily, with or without food as directed by the prescriber. The tablet should be swallowed whole with a glass of water; it should not be crushed, chewed, or broken unless specifically instructed.

The most serious adverse events include severe hepatotoxicity (liver inflammation or failure), hypersensitivity reactions such as Stevens‑Johnson syndrome, and neurological toxicity like peripheral neuropathy. Patients should report any signs of jaundice, rash, fever, or numbness promptly to their healthcare provider.

Nicotibine should be avoided in individuals with known hypersensitivity to isoniazid or any of its excipients. Patients with pre‑existing severe liver disease, acute hepatitis, or those who are unable to take pyridoxine supplementation when required should not be prescribed this medication without careful evaluation.